CClinicalTrials.gg
CompletedNCT03504280Updated Apr 20, 2018

Changes in Serum Vitamin D Level After Different Loading Doses of Cholecalciferol

An interventional study of Cholecalciferol in Hypovitaminosis D, sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Completed. Open to participants aged 21 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-20.

Sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
21 Years to 39 Years
Sex
All
01

Study summary

it is a clinical trial to observe increase in serum vitamin D level and clinical symptoms after 3 different doses of cholecalciferol given either intramuscularly or oral.

Read the detailed description

A prospective, interventional study was conducted in Department of Rheumatology, BSMMU, Dhaka, Bangladesh from October 2015 to January 2017. One hundred and five clinically healthy adults of age 21-39 with serum vitamin D concentration were enrolled in the study. Serum vitamin D level was estimated by chemiluminescent micro particle immunoassay method at baseline and 3 months after the intervention. The participants were divided into three groups using random number table. Group A was given 6 lakh IU of cholecalciferol IM stat dose, group B was given 6 lakh IU of cholecalciferol orally with a glass of milk stat dose and group c was given 2 lakh IU of cholecalciferol orally once a month for 2 months followed by tablet cholecalciferol 1000 IU daily.

02

Conditions studied

  • Hypovitaminosis D

Keywords

  • hypovitaminosis D
  • cholecalciferol
  • mehadose
03

Who can participate

Ages eligible
21 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • hypovitaminosis D (serum 25 OH D \< 20 ng/ml)

Exclusion criteria

Exclusion Criteria:

  • Chronic disease causing Vitamin D deficiency like CKD, nephrotic syndrome, liver disease, hyperparathyroidism, history of skin graft, malabsorption, hyperthyroidism, drugs like anticonvulsants, glucocorticoids, HAART Current pregnancy Lactose intolerance Previously treated with bolus Vitamin D supplementation within previous three months
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Active comparator
    high dose IM

    cholecalciferol 600,000 IU given intramuscularly

    Drug: Cholecalciferol

  • Active comparator
    high dose oral

    cholecalciferol 600,000 IU given orally

    Drug: Cholecalciferol

  • Active comparator
    low dose oral

    cholecalciferol 400,000 IU given orally in 2 divided doses given monthly for 2 consecutive months followed by daily maintenance dose of 1000 IU

    Drug: Cholecalciferol

Interventions

  • DrugCholecalciferol
05

What researchers measure

Primary outcomes

  1. serum 25(OH)D

    serum vitamin D level in ng/ml measured by CLIA method

    Time frame: 3 months

Secondary outcomes

  1. fatigue

    visual analog scale of fatigue during last 7 days of interview measured in 10 cm scale

    Time frame: 3 months

  2. generalized weakness

    visual analog scale of generalized weakness during last 7 days of interview measured in 10 cm scale

    Time frame: 3 months

  3. bone pain

    visual analog scale of bone pain during last 7 days of interview measured in 10 cm scale

    Time frame: 3 months

  4. muscle cramps

    visual analog scale of muscle cramps during last 7 days of interview measured in 10 cm scale

    Time frame: 3 months

  5. pain in weight bearing joints

    visual analog scale of pain in weight bearing joints during last 7 days of interview measured in 10 cm scale

    Time frame: 3 months

  6. difficulty in climbing stairs

    visual analog scale of difficulty in climbing stairs during last 7 days of interview measured in 10 cm scale

    Time frame: 3 months

  7. difficulty in standing from squatting position

    visual analog scale of difficulty in standing from squatting position during last 7 days of interview measured in 10 cm scale

    Time frame: 3 months

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03504280
Lead sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Responsible party
Dr Shweta Nakarmi (Principle Investigator, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh) — Principal investigator
First posted
Apr 20, 2018
Start date
Apr 2015
Primary completion
Aug 2017
Completion
Oct 2017
Last update
Apr 20, 2018

Study contacts

Shweta Nakarmi, resident
principal investigator · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Md Nazrul Islam, professor
study director · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion